US009290814B2

(12) **United States Patent**
Giafis et al.

(10) **Patent No.: US 9,290,814 B2**
(45) **Date of Patent: Mar. 22, 2016**

(54) **MATERIALS AND METHODS FOR DIAGNOSIS OF BLADDER CANCER AND MONITORING RECURRENCE THEREOF**

(71) Applicant: **ABBOTT MOLECULAR INC.**, Des Plaines, IL (US)

(72) Inventors: **Nick Giafis**, Chicago, IL (US); **Irina Sokolova**, Villa Park, IL (US); **Minghao Song**, Lisle, IL (US); **Frank Policht**, Niles, IL (US); **Svetlana Sitailo**, Brookfield, IL (US)

(73) Assignee: **Abbott Molecular Inc.**, Des Plaines, IL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 70 days.

(21) Appl. No.: **13/721,076**

(22) Filed: **Dec. 20, 2012**

(65) **Prior Publication Data**

US 2013/0171637 A1 Jul. 4, 2013

Related U.S. Application Data

(60) Provisional application No. 61/581,797, filed on Dec. 30, 2011.

(51) **Int. Cl.**

C12Q 1/68	(2006.01)
C07H 21/02	(2006.01)
C07H 21/04	(2006.01)

(52) **U.S. Cl.**

CPC ***C12Q 1/6886*** (2013.01); *C12Q 2600/112* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,491,224	A	2/1996	Bittner et al.	
5,756,696	A	5/1998	Gray et al.	
6,008,003	A	12/1999	Haak-Frendscho et al.	
6,573,042	B1	6/2003	Wang	
6,582,908	B2 *	6/2003	Fodor et al.	506/9
6,759,204	B2	7/2004	Benistant et al.	
6,951,926	B2	10/2005	Getzenberg	
6,960,443	B2	11/2005	Reiter et al.	
6,998,232	B1	2/2006	Feinstein et al.	
7,011,950	B2	3/2006	Yung	
7,135,549	B1	11/2006	Challita-Eid et al.	
7,153,700	B1	12/2006	Pardee et al.	
7,192,711	B2	3/2007	Olopade	
7,223,542	B2	5/2007	Raitano et al.	
7,232,655	B2 †	6/2007	Halling	
7,374,897	B2	5/2008	Yuan	
7,374,902	B2	5/2008	Yuan	
7,563,444	B2	7/2009	Challita-Eid et al.	
7,759,077	B2	7/2010	Shariat	
7,776,518	B2	8/2010	Altieri et al.	
7,794,926	B2	9/2010	Altieri et al.	
7,842,458	B2	11/2010	Kanner et al.	
7,862,997	B2	1/2011	Daitho	
7,879,570	B2	2/2011	Challita-Eid et al.	
7,910,316	B2	3/2011	Akiyama et al.	
2005/0252773	A1	11/2005	McBride et al.	
2009/0069194	A1	3/2009	Ramakrishnan	
2013/0078632	A1 *	3/2013	Krishnadath	435/6.11

FOREIGN PATENT DOCUMENTS

EP	1035215	A2	9/2000
EP	1035215	B1	7/2006
EP	2138848	A1	12/2009
EP	2138848	B1	11/2010
JP	2000131321	A	5/2000
JP	2002238599	A	8/2002
JP	2004061288	A	2/2004
JP	2004248508	A	9/2004
JP	2004337120	A	12/2004
WO	9318186	A1	9/1993
WO	9617958	A1	6/1996
WO	2010055467	A1	5/2010

OTHER PUBLICATIONS

Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array (Affymetrix Package Insert for the HG-U133 Plus 2.0 Array, 2003, available via url: <media.affymetrix.com/support/downloads/package_inserts/hgu133_plus_insert.pdf>.*

Ahern, H. The Scientist. Jul. 1995. 9(15): 20-25.*

Zaharieva et al. Int J Cancer. 2003. 117:952-956I.*

Andy Choo K.H., ed., In Situ Hibridization Protocols: Methods in Molecular Biology, vol. 33, Humana Press Inc., 1994, Table of Contents.

Carter N.P., "Methods and Strategies for Analyzing Copy Number Variation Using DNA Microarrays," Nature Genetics, 2007, vol. 39 (Suppl. 7), pp. S16-S21.

Herrick J., et al., "Quantifying Single Gene Copy Number by Measuring Fluorescent Probe Lengths on Combed Genomic DNA,"Proceedings of the National Academy of Sciences, 2000, vol. 97 (1), pp. 222-227.

International Search Report and Written Opinion for Application No. PCT/US2012/070745, mailed on Feb. 5, 2013, 12 pages.

Kallioniemi A., et al., "Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors," Science, 1992, vol. 258 (5083), pp. 818-821.

(Continued)

Primary Examiner — Carla Myers

(74) *Attorney, Agent, or Firm* — Lisa V. Mueller; Michael Best & Friedrich LLP

(57) **ABSTRACT**

A method of diagnosing bladder cancer in a patient comprising contacting a sample of urothelial cells obtained from the patient with a set of detectably labeled probes comprising locus-specific probes for c-myc and AURKA and centromeric probes for chromosomes 7 and 17 under hybridization conditions, and determining the presence of chromosomal abnormalities, wherein the presence of chromosomal abnormalities involving at least two of the detectably labeled probes indicates that the patient has bladder cancer; a method of monitoring recurrence of bladder cancer in a patient; a set of probes comprising locus-specific probes for c-myc and AURKA and centromeric probes for chromosomes 7 and 17; and a kit comprising (a) the set of probes and (b) instructions for diagnosing bladder cancer, or monitoring the recurrence thereof, in a patient.

6 Claims, No Drawings